← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	876	-51	-6%	$17.3B
2	2 Charles River Laboratories CRL $14.4B	264	-4	-1%	$3.57B
3	3 Precigen PGEN $2.64B	191	+11	+6%	$3.42B
4	4 DELISTED bluebird bio BLUE	187	-6	-3%	$1.72B
5	5 DELISTED CATALENT, INC. CTLT	174	-14	-7%	$3.37B
6	ISEE 6 DELISTED IVERIC bio, Inc. Common Stock ISEE	162	+10	+7%	$1.37B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	162	-10	-6%	$2.37B
8	8 DELISTED SANGAMO THERAPEUTICS INC SGMO	143	+2	+1%	$292M
9	9 Sarepta Therapeutics SRPT $1.78B	132	-19	-13%	$686M
10	10 PTC Therapeutics PTCT $4.98B	119	-22	-16%	$190M
11	AGTC 11 DELISTED Applied Genetic Technologies Corporation AGTC	90	+2	+2%	$148M
12	12 DELISTED Adverum Biotechnologies ADVM	82	+6	+8%	$80.1M
13	BLCM 13 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	78	-3	-4%	$149M
14	14 Atara Biotherapeutics ATRA $96M	71	-14	-16%	$377M
15	SIOX 15 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	70	0	0%	$291M
16	16 Lineage Cell Therapeutics LCTX $232M	66	-2	-3%	$99.9M
17	ATHX 17 DELISTED Athersys, Inc. Common Stock ATHX	64	+15	+31%	$21.9M
18	18 Regenxbio RGNX $454M	64	-2	-3%	$180M
19	19 Rocket Pharmaceuticals RCKT $243M	58	-2	-3%	$142M
20	20 uniQure QURE $1.45B	57	-7	-11%	$109M
21	ADAP 21 DELISTED Adaptimmune Therapeutics ADAP	49	0	0%	$260M
22	22 Vericel Corp VCEL $2.06B	49	+9	+23%	$76.7M
23	23 Fate Therapeutics FATE $232M	46	-8	-15%	$28.4M
24	24 Abeona Therapeutics ABEO $249M	45	0	0%	$19.5M
25	25 Cellectis CLLS $113M	44	-4	-8%	$178M